Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Laurence Gordon

Internal Medicine Chicago, IL Doctor of Osteopathy

NPI 1942220900 CMS profile 42885

339 E Grand Ave, Chicago, IL 60611

Open in the dashboard

General payments

$7,246

158 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Laurence Gordon of Chicago, IL is reported in the CMS Open Payments database as having received $7,246 across 158 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $278 6
2022 General $2,347 7
2021 General $2,302 8
2020 General $1,144 18
2019 General $1,176 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laurence Gordon
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Laurence Gordon were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Laurence Gordon Internal Medicine median Middle half National median
2019 $1,176 $159 $48–$570 $163
2020 $1,144 $119 $33–$402 $114
2021 $2,302 $135 $37–$521 $132
2022 $2,347 $141 $42–$496 $149
2023 $278 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Allergan Inc. $2,694 28 payments
  2. GlaxoSmithKline, LLC. $1,825 1 payment
  3. AstraZeneca Pharmaceuticals LP $620 13 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $521 8 payments
  5. Novo Nordisk Inc $379 16 payments
  6. Pfizer Inc. $186 27 payments
  7. Merck Sharp & Dohme Corporation $182 16 payments
  8. Janssen Scientific Affairs, LLC $127 2 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $125 1 payment
  10. Lilly USA, LLC $121 19 payments
  11. Other $465 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,854 152 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,550 3 payments
  3. Consulting Fee $1,825 1 payment
  4. Education $17 2 payments
Products named General payments · program years 2019–2023
  1. UBRELVY Neuroscience $1,750 1 payment
  2. UBRELVY Neuroscience $800 2 payments
  3. JARDIANCE $521 8 payments
  4. FARXIGA $194 6 payments
  5. RYBELSUS $184 2 payments
  6. BREZTRI $170 2 payments
  7. XARELTO $169 5 payments
  8. ELIQUIS $127 12 payments
  9. Kerendia $125 1 payment
  10. CHANTIX $114 13 payments
  11. Other $2,088 199 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

1,939

Median for Internal Medicine: 777

Drug cost

$135,256

Median for Internal Medicine: $73,373

Branded share of claims

13.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 27 $31,705
Eliquis Apixaban Brand 26 $29,745
Xarelto Rivaroxaban Brand 24 $27,547
Ozempic Semaglutide Brand 11 $17,762
Esomeprazole Magnesium Generic 15 $2,741
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $2,501
Celecoxib Generic 27 $1,770
Atorvastatin Calcium Generic 282 $1,666
Synthroid Levothyroxine Sodium Brand 14 $1,627
Omeprazole Generic 144 $1,531

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$9,862

Of which drugs: $2,337

Medicare patients

104

Average age 70

Services billed

274

54 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 38%
Depression 28%
Diabetes 27%
Heart failure 27%
Chronic kidney disease 26%
Ischemic heart disease 23%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record